The estimated Net Worth of Advisors Llcperceptive Life... is at least 1.53 百万$ dollars as of 22 September 2020. Advisors Life owns over 1,058,824 units of Athira Pharma stock worth over 1,526,254$ and over the last 4 years Advisors sold ATHA stock worth over 0$.
Advisors has made over 1 trades of the Athira Pharma stock since 2020, according to the Form 4 filled with the SEC. Most recently Advisors bought 1,058,824 units of ATHA stock worth 18,000,008$ on 22 September 2020.
The largest trade Advisors's ever made was buying 1,058,824 units of Athira Pharma stock on 22 September 2020 worth over 18,000,008$. On average, Advisors trades about 352,941 units every 0 days since 2020. As of 22 September 2020 Advisors still owns at least 3,114,805 units of Athira Pharma stock.
You can see the complete history of Advisors Life stock trades at the bottom of the page.
Advisors's mailing address filed with the SEC is 51 ASTOR PLACE, 10TH FLOOR51 ASTOR PLACE, 10TH FLOOR, , NEW YORKNEW YORK, NYNY, 1000310003.
Over the last 4 years, insiders at Athira Pharma have traded over 100,296$ worth of Athira Pharma stock and bought 5,411,219 units worth 62,123,025$ . The most active insiders traders include Advisors Llcperceptive Life...、Investments, Lpwong Roderic...、Joseph Edelman. On average, Athira Pharma executives and independent directors trade stock every 33 days with the average trade being worth of 62,547$. The most recent stock trade was executed by Andrew Gengos on 3 September 2024, trading 1,272 units of ATHA stock currently worth 725$.
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in LIFT-AD Phase II/III and ACT-AD Phase II clinical trials for the treatment of mild-to-moderate Alzheimer's disease, as well as in clinical development for Parkinson's disease. The company also develops product candidates, which are in preclinical stage, including ATH-1019/ATH-1020 for neuropsychiatric conditions; and ATH-1018 for peripheral nervous system disorders, such as neuropathy. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
Athira Pharma executives and other stock owners filed with the SEC include: